Business Wire

Vidac Pharma Reports Positive Results from Phase 2a Proof-of-Concept Trial of VDA-1102 Ointment in Actinic Keratosis

Del

Vidac Pharma, a clinical-stage dermatology- and oncology-focused biopharmaceutical company, today announced positive results from a Phase 2a Proof-of-Concept (POC) clinical trial for its investigational topical drug, VDA-1102 ointment, in subjects with actinic keratosis (AK), an early form of cutaneous squamous cell carcinoma (cSCC). These results establish VDA-1102 ointment as a potential first-in-class non-irritating treatment for AK.

According to Dr. Mark Lebwohl, Professor and Chairman of Dermatology at the Icahn School of Medicine at Mount Sinai and an investigator in this trial, "the results of this trial are exciting because, until now, all the treatments we have available for actinic keratoses are irritating. We need nonirritating AK treatments that don't cause crusting and scabbing on the face."

“There is a high unmet need for an effective treatment of actinic keratoses without unpleasant skin reactions. Based on the results of this first study, VDA-1102 ointment appears to successfully go in this direction," said Professor Kristian Reich, Founder of SkinflammationTM, Hamburg, Germany.

“This proof-of-concept study established VDA-1102 ointment's safety and tolerability, demonstrating that it is completely non-irritating,” said Dr. Chaim M. Brickman, Chief Medical Officer at Vidac. “The study also confirmed VDA-1102 ointment’s efficacy in AK and paves the way for a higher dose, longer duration confirmatory Phase 2b study, which is planned for 2018.”

The randomized, double-blind, placebo-controlled, parallel-cohort Phase 2a clinical trial investigated the efficacy, safety, tolerability, and pharmacokinetics of once-daily application of topical VDA-1102 ointment for 28 days in subjects with actinic keratosis on their face or scalp (25 cm2 treatment area with 4-8 discrete Grade 1 or 2 AK lesions at baseline). Study endpoints were evaluated on Day 56. The study enrolled 93 subjects, at 8 clinical sites in the U.S. and Israel. Subjects were randomized to three treatment cohorts (5%, or 10% VDA-1102 ointment, or placebo). The mean age of the enrolled subjects was 66.5 (ranging from 37 to 93 years), and the majority of subjects (75.3%; 70 subjects) were treated for AK lesions on the face.

Safety – There were no treatment-emergent serious adverse events (AEs) or severe AEs related to the study drug. None of the subjects on the active study drug withdrew consent, discontinued treatment, or applied an emollient to the treatment field. Only 2 treatment-emergent AEs were deemed related to the study drug in the active treatment arms. Both AEs were mild and occurred in the 5% treatment group; none were reported in the 10% group. There were no clinically significant findings in vital signs, physical examinations, clinical laboratory results, or ECGs.

Tolerability – VDA-1102 ointment treatment resulted in no local skin irritation as measured by a Local Skin Reaction (LSR) score that ranges from 0 to 4 for 9 possible findings including erythema, edema, scaling, itching, and pain. On this 36-point LSR scale, the mean maximal scores for the VDA-1102 ointment treatment groups were 1.1±2.0 and 0.9±1.5 for the 5% and 10% doses, respectively, compared to 0.8±1.3 in the placebo treatment group. There was no statistical difference in the mean composite LSRs between the three treatment groups at any time (p= 0.7821).

Efficacy –The primary efficacy endpoint of the study was reduction in the total number of AK lesions (of all Grades) in the treatment field on Day 56. The 10% VDA-1102 ointment demonstrated statistically significant reduction in the total number of AK lesions vs. placebo for subjects treated on their face (p=0.023; 70 subjects), showing 50% median reduction with 10% VDA-1102 ointment (mean 38.8%±36.4%) compared to a median reduction of 20% in the placebo group (mean 29.0%±32.5%). The mean reduction in AK lesion count was greater in the 10% VDA-1102 ointment group than in the placebo group for the combined face or scalp population as well (32.1%±34.1% and 27.8%±30.6%, respectively) although the difference was not statistically significant.

The 10% VDA-1102 ointment treatment also demonstrated a statistically significant (p=0.0004) effect in an additional efficacy endpoint, reduction in the number of the more advanced lesions (only Grade 2 or 3; not counting Grade 1 lesions) for subjects treated on their face, with a median reduction of 64.6% (mean 59.9%±38.6%) compared with a median reduction of 0% in the placebo group (mean 19.9%±72.0%). This effect was even more prominent in the Per-Protocol population (N=83) where the median reduction of Grade 2 (or 3) AK lesions on the face was 80% in the 10% VDA-1102 ointment group compared to a median reduction of 0% in the placebo group. Reduction in Grade 2 (or 3) AK lesions was also statistically significant in the combined face and scalp populations (p=0.029), demonstrating a median reduction of 56.3% for the 10% VDA-1102 ointment group (mean 53.1%±41.9%) compared to a 0% median reduction in the placebo group (mean 25.9%±69.8%).

No Grade 3 lesions developed during the study in the two VDA-1102 ointment treatment groups, while 2 subjects in the placebo treated groups developed at least one Grade 3 lesion, despite having no Grade 3 lesions at baseline. A confirmatory Phase 2b study for VDA-1102 ointment in AK is planned for 2018.

About VDA-1102 ointment

VDA-1102 is a novel, potent selective modulator of the VDAC/HK2 complex in cancer cells. The drug triggers the dissociation of HK2 (hexokinase 2) from mitochondrial VDAC (voltage dependent anion channel) leading, among other effects, to apoptosis and death of the malignant cells. The selective nature of VDAC/HK2 dissociation targets only cancer cells without affecting the surrounding healthy tissue. VDA-1102 is being developed as a topical ointment for treatment of actinic keratosis (AK), cutaneous squamous cell carcinoma (cSCC), and cutaneous T-cell lymphoma (CTCL). VDA-1102 ointment has successfully completed a Phase 2a proof-of-concept study in subjects with AK, demonstrating efficacy, safety, and tolerability. VDA-1102 is also being developed as an injectable for treatment of solid tumors.

About Actinic Keratosis

Actinic keratosis (AK) is one of the most common dermatologic conditions worldwide. It affects an estimated 58 million people in the United States alone. In 2015 the global AK market was estimated at $6.6 billion. This skin disease occurs predominantly in older males with fair skin and most often begins as a rough red patch on the face, scalp, and/or extremities that may progress to a thicker, scaly, and unsightly skin lesion. AK is considered by many as an early form of cSCC. Thus, treatment is most commonly recommended by physicians in order to prevent cSCC. Current therapies are inadequate and pose significant disadvantages to public health. The limited tolerability of current treatment options greatly decreases the willingness of patients to be treated, compliant, and/or retreated. AK is a chronic disease for which patients often require repeat treatments. As a result patients with this prevalent condition elect to avoid treatment, seeking medical help only later, after their lesions have become esthetically intolerable or have advanced to malignant cSCC tumors.

About Vidac Pharma

Vidac Pharma is an innovative clinical-stage oncology- and dermatology-focused pharmaceutical company, developing novel drugs to help people suffering from a range of diseases. Vidac’s breakthrough technology targets the VDAC/HK2 system that is unique to malignant cells. The mechanism-of-action of these drugs leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue, leading to well-tolerated and efficacious treatments. Vidac is developing VDA-1102 as a topical treatment for AK and other skin malignancies, and as a parenteral drug for treatment of solid tumors. For more information regarding Vidac Pharma, please visit www.vidacpharma.com.

Contact information

Vidac Pharma
Shelly Majar, +972-2-5952090
smajar@vidacpharma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

MobileIron Recognized as a Partner in Google Led Android Enterprise Recommended Program for Enterprise Mobility Management Providers15.1.2019 17:20Pressemelding

MobileIron (NASDAQ:MOBL), the secure foundation for modern work, today announced that it has been recognized by Google™ as a partner in its Android Enterprise Recommended program for Enterprise Mobility Management (EMM) providers. Android™ Enterprise Recommended validates those EMM solutions that meet an elevated set of requirements defined by Google, delivering advanced Android Enterprise features that are supported by highly knowledgeable teams specializing in modern Android security and management. “Enterprise transformation will be central to the second decade of Android computing. Offerings like Android Enterprise Recommended, OEM Config, and Google Play Protect create the perfect storm to support the millions of Android devices that are increasingly making their way to the enterprise,” said Simon Biddiscombe, CEO, MobileIron. “MobileIron is pleased to be a partner in the Android Enterprise Recommended program for EMMs. We are confident that our expertise in endpoint and device se

INDYCAR Names NTT as Entitlement Sponsor of IndyCar Series15.1.2019 17:20Pressemelding

INDYCAR announced today during the North American International Auto Show that global information technology and communications leader NTT has signed a multi-year agreement to become the IndyCar Series Title Partner. In addition, NTT becomes the Official Technology Partner of INDYCAR, the IndyCar® Series, Indianapolis Motor Speedway, the Indianapolis 500 and NASCAR’s the Brickyard 400 beginning in 2019. INDYCAR will partner with NTT to deliver digital innovations that enhance the fan experience. These innovations include the evolution of INDYCAR’s mobile application and adoption of NTT’s proprietary Smart Platform to support the sport and its venues in delivering better insights into the racing series. “NTT is proud to be associated with INDYCAR and accelerate the future of smart racing. Technological innovations have the potential to change the sport and fan experience drastically,” said Jun Sawada, President and CEO of NTT. “NTT, along with our partners, aims to bring the Smart World

CSC Extends Fund Administration Reach into Asia Pacific15.1.2019 15:00Pressemelding

CSC has extended their private equity and real estate fund administration services into Asia. Third-party oversight of private equity and real estate funds is increasing due to the growing demand from investors for greater transparency and help navigating the regulatory requirements in this dynamic landscape. “A number of factors are creating opportunities in the private equity market in Asia, including strong deal growth, increasing reporting demands from investors, and pressure to commit unspent capital,” says Bill Popeo, president of CSC’s Global Financial Markets business. Liam McHugh, Fund Administration managing director, is leading the efforts in Asia, with office locations in Singapore, Hong Kong, and Shanghai. Prior to joining CSC, McHugh served in various executive capacities at Apex Fund Services and Equinoxe Alternative Investment Services in the APAC region and Ireland. “CSC’s private ownership status ensures the stability that is required of a service provider in a fragme

UAEREP’s First Cycle Awardees Present Outstanding Final Project Results At the 3rd IREF15.1.2019 14:29Pressemelding

The UAE Research Program for Rain Enhancement Science’s 3rd International Rain Enhancement Forum (IREF) today featured the final project results of its 1st Cycle awardees at the 2019 Abu Dhabi Sustainability Week (ADSW). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190115005523/en/ 3rd International Rain Enhancement Forum Reveals Results of the Researches of its First Cycle (Photo: AETOSWire) In the presence of a distinguished audience of VIP dignitaries, diplomats, stakeholders and scientists, Dr Linda Zou, Professor Volker Wulfmeyer, Professor Masataka Murakami, presented the final results of innovative research advancing rain enhancement science in the UAE and beyond. The three awardees that presented the successful outcomes of original research projects completed within a 3-year time scale are: Professor Linda Zou, a Professor at the Khalifa Institute of Science and Technology, has fabricated, tested and validated nove

Enterprises Will Increase Digital Technology Investment and Adoption in 2019 According to Study by Economist Intelligence Unit and DXC Technology15.1.2019 14:00Pressemelding

A vast majority of businesses will increase their investments in digital technology over the coming year, and many expect IT modernization to fuel future transformation efforts that lead to cost savings and greater profitability. These are some of the findings from a new global survey conducted by The Economist Intelligence Unit (EIU) and commissioned by DXC Technology (NYSE: DXC), the world’s leading independent, end-to-end IT services company. The study, “2019: The Year of Digital Decisions,” explores how companies define digital transformation and the resulting business outcomes. Significantly, the report reveals that more than eight in ten survey respondents (83 percent) expect their organizations to increase their digital investments in 2019. And more than 40 percent of respondents predict that their organizations will increase their investments by 11 percent or more. Currently, approximately half of companies surveyed have digitally enabled just three key organizational functions

TDK's Subsidiary TDK-Lambda Uses Transphorm GaN to Advance PFH Series AC-DC Power Supply15.1.2019 13:00Pressemelding

Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and only qualified high-voltage (HV) Gallium Nitride (GaN) semiconductors—today confirmed that leading power supply manufacturer TDK-Lambda, a group company of TDK, has released its first GaN-based AC-DC power supply. The full function 504 W rated PFH500F-28 is the company’s latest generation AC-DC baseplate cooled power supply module. Further, the power module is the latest Transphorm customer product to demonstrate the HV GaN advantages, increasing efficiency by 5 percent in a 28 percent smaller package over the previous PFE500F series. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190115005041/en/ TDK-Lambda's PFH500F-28 AC-DC power supply module uses Transphorm's GaN modules for a 30% power density increase. (Graphic: Business Wire) Broad Industrial Applications Get a Boost The PFH500F-28 is a low-profile power module with 28 volts of